Adicet Bio (NASDAQ: ACET) reported a fourth‑quarter 2025 loss of $2.94 per share, beating the consensus estimate of $3.23 per share by $0.29. The company’s loss narrowed from $5.06 per share in the same quarter a year earlier, reflecting tighter cost control and a more efficient clinical‑pipeline spend profile.
The full‑year 2025 results show a net loss of $16.95 per share, an improvement from $21.33 per share in 2024. Revenue for the year was $0, as the company has not yet generated product sales and relies on collaboration arrangements for cash inflows. Cash and cash equivalents stood at $158.5 million as of December 31, 2025, providing a runway into the second half of 2027.
Research and development expenses were $99.1 million in 2025, slightly down from $99.3 million in 2024, while general and administrative costs fell to $23.0 million from $28.3 million. The modest expense reductions helped offset the lack of revenue and contributed to the narrowed loss per share.
"Adicet closed the year with solid momentum, driven by strong enrollment progress and the positive data from the prula‑cel Phase 1 autoimmune study reported during the fourth quarter. Enrollment in our Phase 1 prula‑cel autoimmune study continues advancing ahead of expectations, supported by significant physician and patient interest in the study and FDA alignment that enables outpatient dosing for LN and SLE patients. We look forward to providing a clinical update in LN, SLE and SSc in the first half of this year." – Chen Schor, President and CEO. "Beyond prula‑cel, we expect to submit a regulatory filing for ADI‑212 for the treatment of mCPRC in the third quarter of 2026 with enrollment expected to begin in the fourth quarter of 2026. Adicet is well positioned for continued execution and poised to deliver meaningful, value‑driving milestones in the year ahead." – Chen Schor.
Investors remained cautious after the earnings release, likely due to the company’s pre‑revenue status and ongoing operational challenges. The earnings beat was tempered by the absence of product sales and the need to sustain heavy R&D investment to advance the prula‑cel and ADI‑212 programs.
The results underscore Adicet’s focus on clinical development and its ability to manage costs while accelerating enrollment in key trials. The company’s strong cash position and modest expense growth suggest it can continue to fund its pipeline through 2027, but the lack of revenue and the need for future regulatory filings remain significant headwinds for long‑term profitability.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.